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Apolipoprotein A-II (apoA-II) is the second most abun-
dant protein in HDLs. Genetic studies in humans have
provided evidence of linkage of the apoA-II gene locus
to plasma free fatty acid (FFA) levels and to type
2 diabetes, and transgenic mice overexpressing mouse
apoA-II have elevated levels of both FFA and triglycer-
ides. We now show that apoA-II promotes insulin resis-
tance and has diverse effects on fat homeostasis.
ApoA-II transgenic mice have increased adipose mass
and higher plasma leptin levels than C57BL/6J control
mice. Fasting glucose levels were similar between
apoA-II transgenic and control mice, but plasma insulin
levels were elevated approximately twofold in the
apoA-II transgenic mice. Compared with control mice,
apoA-II transgenic mice exhibited a delay in plasma
clearance of a glucose bolus. Adipose tissue isolated
from fasted apoA-II transgenic mice exhibited a 50%
decrease in triglyceride hydrolysis compared with adi-
pose tissue from control mice. This is consistent with a
normal response of adipose tissue to the increased
insulin levels in the apoA-II transgenic mice and may
partially explain the increased fat deposition. Skeletal
muscle isolated from fasted apoA-II transgenic mice
exhibited reduced uptake of 2-deoxyglucose compared
with muscles isolated from control mice. Our observa-
tions indicate that a primary disturbance in lipoprotein
metabolism can result in several traits associated with
insulin resistance, consistent with the hypothesis that
insulin resistance and type 2 diabetes can, under certain
circumstances, be related primarily to altered lipid
metabolism rather than glucose metabolism. Diabetes
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T
he HDLs protect against the development of
atherosclerosis, the major cause of heart disease
and stroke, but the precise mechanisms involved
are unclear. Most studies have focused on the
role of HDL in reverse cholesterol transport and its
antioxidant functions, two pathways by which HDLs are
believed to protect against atherosclerosis (1,2). The major
protein components of HDL are apolipoprotein (apo)A-I and
apoA-II. ApoA-I clearly functions in cholesterol transport
and is required for HDL assembly, consistent with the
observation that increased levels of apoA-I protect against
the development of atherosclerosis (3–5). The role of
apoA-II, however, is unknown. ApoA-II appears to im-
pair the reverse cholesterol transport and antioxidant
functions of HDL, consistent with the observation that
increased apoA-II levels promote the development of
atherosclerosis (3,6–9). Also, genetic studies in both
mice and humans have shown that the levels of plasma
free fatty acids (FFAs) segregate with the apoA-II locus
(10).
Insulin resistance is associated with a cluster of meta-
bolic abnormalities, termed the “insulin resistance syn-
drome,” including increased adiposity, elevated insulin
levels, elevated plasma triglyceride levels, low HDL levels,
and hypertension (11,12). These traits are strongly associ-
ated with several chronic diseases including atherosclero-
sis and type 2 diabetes. The interrelationships among
these altered metabolic traits are poorly understood, al-
though shared genetic factors are clearly involved. Human
genetic studies have resulted in the identiﬁcation of cer-
tain loci contributing to common forms of type 2 diabetes,
adiposity, leptin levels, and plasma triglyceride levels, but
the underlying genes are largely unknown (13,14). Bio-
chemical approaches have helped to deﬁne disturbances
in processes such as insulin signaling and glucose trans-
port, but the primary defects responsible for common
forms of insulin resistance have not been revealed. A
major obstacle to the analysis of the insulin resistance
syndrome is the considerable genetic heterogeneity, com-
pounded by important environmental inﬂuences.
We have used genetic studies of animal models to
address the problem. Animal models reduce the complica-
tions of genetic heterogeneity and environmental inﬂu-
ences, and genetic crosses with animal models have much
greater power to detect linkage compared with genetic
studies in humans (15). In genetic crosses among common
inbred strains of mice, we identiﬁed the apoA-II gene as an
important genetic factor contributing to plasma lipopro-
tein levels, FFA levels, and atherosclerosis (10,16). Subse-
quently, we observed, by nonparametric linkage analysis,
that variations of the apoA-II gene in humans contribute to
the levels of apoA-II, FFAs (10), and plasma apoA-I (17).
Transgenic mice overexpressing mouse apoA-II (6,7) or
human apoA-II (8) were subsequently constructed and
studied. Consistent with mouse genetic studies, the mouse
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levels, whereas the human apoA-II transgene resulted in
variable changes in HDL levels. Mice expressing the
transgene for either human or mouse apoA-II exhibited
increased susceptibility to atherosclerosis (6,8). The
transgenic mice overexpressing mouse apoA-II also
exhibited elevated levels of triglycerides, and the plasma
lipoproteins promoted accumulation of lipid hydroperox-
ides (2,7), consistent with the accelerated atherogenesis.
Subsequently, mice lacking apoA-II were constructed by
gene targeting (18). Consistent with previous genetic stud-
ies, the mice showed reduced HDL cholesterol levels and
accelerated clearance of triglyceride-rich lipoproteins.
The apoA-II-null mice also showed evidence of increased
sensitivity to insulin, suggesting a role of apoA-II in insulin
metabolism (18). Based on these results, and the hypertri-
glyceridemia and elevated FFA levels observed in apoA-II
transgenic mice, we have further explored the possible
inﬂuence of apoA-II expression on traits associated with
insulin resistance.
We now report that increased expression of apoA-II can
contribute to insulin resistance and altered body fat ho-
meostasis. These data provide evidence for the concept
that primary alterations in plasma lipid metabolism may
contribute to various metabolic syndromes associated
with type 2 diabetes.
RESEARCH DESIGN AND METHODS
Animals. Transgenic mice containing multiple copies of the mouse apoA-II
gene were derived as described previously (6). To eliminate genetic variation,
the apoA-II transgene was isolated on a C57BL/6J background by backcross-
ing for .10 generations. Male mice homozygous for the transgene and
age-matched controls (4–6 months) were used in all experiments. ApoA-II
levels in transgenic mice were elevated about ﬁvefold, whereas apoA-I levels
were similar to those of controls (7) (data not shown). Animals were housed
four to ﬁve to a cage, maintained at 25°C on a 12-h light-dark cycle, and
provided Harlan-Teklad rodent diet (6% fat) and water ad libitum. The care of
the mice, as well as all procedures used in this study, were done in accordance
with National Institutes of Health animal care guidelines.
Whole body fat determinations. The percentage of total body fat was
determined as described previously (19). Brieﬂy, the animals were killed, and
the carcasses were dried to remove all water. They were then homogenized,
and the lipid was extracted from an aliquot of the homogenate using a soxhlet
apparatus. The lipid content of the homogenate was determined by gravimet-
ric analysis.
Lipid analyses. Plasma was collected from mice that were fasted overnight
and bled 2–3 h after the beginning of the light cycle from the retro-orbital
plexus under isoﬂorane anesthesia. Total cholesterol, HDL cholesterol, tri-
glycerides, and FFA concentrations were determined as described (2,20). HDL
was isolated by precipitation of VLDL and LDL with heparin and manganese
chloride (21). Each lipid determination was measured in triplicate. An
external control sample with known analyte concentration was run in each
plate to assure accuracy.
Skeletal muscle triglyceride content. The hindquarters of anesthetized (50
mg/kg Nembutal) mice were ﬂushed thoroughly with 25 ml heparinized
phosphate-buffered saline that was administered via the abdominal aorta at a
ﬂow rate of 6 ml/min. All visible adipose tissue was removed from sections of
the soleus and gastrocnemius muscles under a dissecting microscope. Ali-
quots of muscle tissue were then homogenized, and total lipids were extracted
by the method of Folch et al. (22). Triglyceride mass was determined as
described above.
Skeletal muscle 2-deoxy-[U-
14C]glucose uptake. After an overnight fast,
mice were anesthetized with pentobarbital (50 mg/kg body wt), and the soleus
muscle was isolated under a dissecting microscope as described previously
(23). In one set of experiments, the muscles were weighed and immediately
incubated for 20 min in Krebs-Henseleit buffer under 95% O2:5% CO2, which
contained 5.5 mmol/l glucose, 1% bovine serum albumin (BSA), 2-deoxy-[U-
14C]glucose (2.5 mCi/ml), and no exogenous insulin added. At the end of the
experiment, the tissue was immediately immersed in an ice-cold saline (0.9%)
rinse and then washed in ice-cold saline for1ht oremove the radioactive label
that was in the extracellular space of the muscle, as described previously (23).
The uptake studies were repeated in a second set of experiments in which
exogenous insulin was added to the incubation media. In these experiments,
the soleus muscles were preincubated for 20 min in the same buffer used in
the previous set of experiments, except that porcine insulin was present at a
concentration of 2 mU/ml. This concentration was reported to provide
maximal stimulation of glucose uptake in rat soleus muscle (24). After the
preincubation, the tissue was transferred to another vessel that contained
fresh media (also containing 2 mU/ml insulin) and 2-deoxy-[U-
14C]glucose,
and the rates of uptake were determined as described previously.
Plasma apoB determinations. ApoB48 and apoB100 concentrations were
determined by a combination of SDS-PAGE and immunoblotting in animals
that had been fasted overnight. Plasma samples and molecular weight markers
were run on 4–20% gradient gels (Novex). Plasma samples were diluted 1:25
in sample buffer (10% 2-mercaptoethanol, 0.25 mol/l Tris-HCl, pH 6.8, 0.2%
SDS, 20% glycerol, and 0.025% bromothymol blue), and 20 ml of each sample
preparation was loaded. The gels were electrophoresed at 25 mA for 2 h. The
proteins were then transferred to nitrocellulose using a wet blotter, probed
with rabbit anti-rat apoB antibody, visualized by chemiluminescence (Amer-
sham), and quantitated by densitometry. Data are expressed in relative densi-
tometry units.
Determination of plasma B-hydroxybutyrate and lactic acid. Plasma
concentrations of b-hydroxybutyrate and lactic acid were determined in mice
that had been fasted overnight. Blood was collected as described above. To
obtain accurate plasma lactate concentrations, the blood collection tubes
were prechilled on ice, and the samples were centrifuged within 5 min to
remove the erythrocytes. Plasma b-hydroxybutyrate and lactate concentra-
tions were both determined in duplicate measurements (kits 310-A and 735-10
for b-hydroxybutyrate and lactate, respectively; Sigma, St. Louis, MO).
Lipoprotein lipase and hepatic lipase activities. The activities of lipopro-
tein lipase and hepatic triglyceride lipase were measured in plasma from mice
that had been fasted overnight. The animals were bled from the retro-orbital
TABLE 1
Concentration of plasma lipids and lipase activities in apoA-II transgenic and control mice
Nontransgenic mice Transgenic mice
Total cholesterol (mg/dl) 101 6 18 (35) 247 6 18* (35)
HDL cholesterol (mg/dl) 65 6 4 (35) 127 6 8* (35)
VLDL 1 LDL cholesterol (mg/dl) 36 6 2 (35) 120 6 9* (35)
Triglycerides (mg/dl) 47 6 6 (35) 426 6 24* (35)
FFA (mmol/l) 0.9 6 0.1 (35) 4.5 6 0.4* (35)
b-Hydroxybutyrate (mg/dl) 18 6 2 (12) 17 6 2 (12)
Lactate (mg/dl) 17 6 1 (12) 19 6 2 (12)
LPL activity (dpm FFA z h
21 z ml
21 plasma) 11,200 6 950 (11) 10,750 6 780 (11)
HTGL activity (dpm FFA z h
21 z ml
21 plasma) 5,325 6 350 (11) 4,950 6 475 (11)
Skeletal muscle triglycerides (mg/g tissue) 12.98 6 0.45 (3) 18.58 6 1.79* (3)
Data are means 6 SE (n). Control and apoA-II transgenic mice were bled after an overnight fast. Plasma concentrations of total cholesterol,
HDL cholesterol, triglycerides, FFA, lactate, and b-hydroxybutyrate, as well as activities of lipoprotein lipase (LPL) and hepatic triglyceride
lipase (HTGL) were determined as described in RESEARCH DESIGN AND METHODS. *Signiﬁcantly different from controls (P , 0.05), determined by
the Student’s t test.
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vein. Assays were done using the tri-[1-
14C]oleoylglycerol substrate as de-
scribed (25).
Leptin, insulin, and glucose assays. Plasma leptin and insulin levels were
determined in duplicate by enzyme-linked immunosorbent assay (ELISA)
using kits from R&D Systems (catalog no. MOBOO) and Crystal Chemical
(catalog no. IVSKR020), respectively. The intra-assay precision for the insulin
assay is 3.5% and 3.8% for the leptin assay. The interassay precision for the
insulin assay is 6.3% and 5.8% for the leptin assay. The minimum detectable
level of mouse leptin is ,22 pg/ml and is 156 pg/ml for mouse insulin. Plasma
glucose concentrations were determined in triplicate using a commercially
available kit (Sigma, no. 315-100). In experiments where glucose concentra-
tions were determined, blood collection and plasma isolation was carried out
as described for the lactate determinations to minimize glucose metabolism
by erythrocytes.
Intraperitoneal glucose tolerance tests. Glucose tolerance tests were
done essentially as previously described (26). Animals were fasted overnight
and 50 ml of blood was drawn from the retro-orbital plexus under isoﬂorane
anesthesia. A bolus of glucose (20% wt/vol in sterile lipoprotein lipase–free
H2O) was then injected into the peritoneal cavity (2 mg/g body wt). Blood
samples were drawn from the retro-orbital plexus at 10, 20, 30, and 90 min
after injection, and plasma glucose and insulin concentrations were deter-
mined as described above. To reduce the stress effects of repeated sampling,
each animal underwent only one postinjection bleed, with different animals
bled at each time point. Two-way analysis of variance, after logarithmic
transformation to equalize variances among the groups, was used to compare
the glucose and insulin curves between the control and apoA-II transgenic
groups. The Tukey studentized range method was used for comparison of
individual points. Each area under the curve (AUC) from time 0 to 90 min was
estimated by the trapezoidal rule. Percentage differences of AUCs between
control and transgenic groups are expressed as the estimate 6 asymptotic SE.
Adipose tissue metabolism. Aliquots of epididymal and retroperitoneal fat
pads from overnight fasted apoA-II transgenic and control mice were incu-
bated in William’s Media E, containing 5% fetal bovine serum, 200 mg/ml
gentamicin, and 10 mmol/l HEPES, pH 7.4, for1ha t37°C in a shaking water
bath. Aliquots of the media were then centrifuged to remove debris, and the
glycerol concentration was determined. The difference in glycerol concentra-
tion between the media blank and the adipose tissue incubations represented
glycerol released from hydrolysis of triglycerides. The data are expressed as
milligram of triglyceride released per hour per gram of tissue.
RESULTS
We previously reported the development of transgenic
mice overexpressing mouse apoA-II on the genetic back-
ground of strain C57BL/6J (6,7). The mice exhibited ele-
vated levels of HDL cholesterol, as well as triglyceride-rich
lipoproteins, compared with C57BL/6J mice (Table 1).
Consistent with the mouse and human studies, which
demonstrated a correlation between apoA-II and plasma
FFA, we observed about a ﬁvefold increase in the levels of
FFA in the apoA-II transgenic mice relative to controls
(Table 1). Despite the markedly increased plasma FFA
levels, plasma concentrations of b-hydroxybutyrate and
lactate were similar between apoA-II transgenic and con-
trol mice (Table 1).
The hypertriglyceridemia in the apoA-II transgenic mice
does not appear to be due to differences in lipoprotein
lipase or hepatic lipase because the activities of both were
similar between control and transgenic mice (Table 1). We
determined the ratio of apoB48 to apoB100 in the plasma
from fasted animals and found the proportion of apoB48 to
be signiﬁcantly increased in the apoA-II transgenic mice
compared with controls (Fig. 1).
Although plasma glucose levels after fasting were not
signiﬁcantly elevated in the apoA-II transgenic mice, fast-
ing insulin levels were elevated approximately twofold
(Fig. 2). To further test whether the apoA-II transgenic
FIG. 1. The ratio of apoB48 to apo100 is increased in the plasma of
apoA-II transgenic mice. ApoB48 and apoB100 concentrations were
determined in plasma from apoA-II transgenic and control mice that
had been fasted overnight. The apolipoproteins were isolated by
SDS-PAGE followed by immunoblotting, visualized by chemilumines-
cence, and quantitated by densitometry. Data are expressed in relative
densitometry units. n 5 4 for both apoA-II and control groups. The
Student’s t test was used to test for differences between control and
apoA-II transgenic mice. *Signiﬁcantly different from control (P <
0.05).
FIG. 2. Plasma insulin concentrations are increased in the apoA-II transgenic mice. ApoA-II transgenic and control mice that had been fasted
overnight were bled, and plasma glucose and insulin levels were determined. A: Glucose levels expressed in milligrams per deciliter. B: Insulin
levels expressed in picograms per milliliter. All values are given as the mean 6 SE. n 5 15 for both control and apoA-II transgenic groups. The
Student’s t test was used to test for differences between control and apoA-II transgenic mice. *Signiﬁcantly different from control (P < 0.05).
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of glucose clearance after intraperitoneal injection of a
bolus of glucose. Figure 3 shows a representative experi-
ment in which a signiﬁcant and reproducible delay in the
clearance of glucose was observed in the apoA-II trans-
genic mice compared with controls. The area under the
glucose curve was increased 28 6 7% (P , 0.001) in the
apoA-II transgenic group compared with controls. The
AUC above baseline glucose levels was also higher in the
transgenic group (increased 36 6 13% over controls, P ,
0.001). Plasma insulin concentrations were also deter-
mined throughout the glucose clearance studies and dem-
onstrated that insulin secretion was not impaired in the
apoA-II transgenic mice (Fig. 3). The AUC for the unad-
justed insulin values was increased 123 6 34% (P 5 0.001)
in the apoA-II transgenic mice compared with control
mice. The AUC above baseline insulin levels for the
transgenic group was 118 6 183% higher than that of
controls, but this was not statistically signiﬁcant. The
insulin-to-glucose ratios were also signiﬁcantly increased
in the apoA-II transgenic mice compared with controls at
all time points (0 time: 5.72 6 0.55 vs. 11.87 6 1.35, P 5
0.0007; 10 min: 2.78 6 0.60 vs. 5.46 6 0.99, P 5 0.0342; 20
min: 2.91 6 0.29 vs. 4.60 6 0.67, P 5 0.0311; 30 min: 2.60 6
0.16 vs. 4.13 6 0.623, P 5 0.0308; 90 min: 2.75 6 0.18 vs.
6.96 6 1.06, P 5 0.0012).
The strong association between fat stores and insulin
resistance prompted us to examine fat metabolism in the
apoA-II transgenic mice. Although body weights were only
slightly increased in the apoA-II transgenic mice compared
with age-matched controls, the apoA-II transgenic mice had a
striking increase in fat pad mass, including both the retro-
peritoneal and epididymal fat (Fig. 4). The masses of the
omental and subcutaneous fat pads were also markedly
increased in the apoA-II transgenic mice compared with
controls (data not shown); however, both of these fat de-
pots, and in particular, the omental fat depots, were fre-
quently too small in the control animals to allow accurate
quantitation. Whole body fat content was increased ;45%
in the apoA-II transgenic mice, similar to the percent in-
crease observed in both the retroperitoneal and epididymal
fat pads (Fig. 4). Thus, all fat depots in the apoA-II trans-
genic mice appeared to be increased to a similar extent
compared with their counterparts in the control animals
with no change in the regionalization of the fat deposits.
Consistent with the increase in adipose tissue, leptin levels
were elevated about twofold in the plasma of apoA-
II transgenic mice compared with control mice (Fig. 4).
Because intracellular accumulation of triglycerides in
muscle is frequently associated with the development
of insulin resistance, the triglyceride content of skeletal
muscle was also determined. The triglyceride mass in
skeletal muscle was signiﬁcantly increased in the apoA-II
transgenic mice compared with control mice (Table 1).
Because the apoA-II transgenic mice exhibited in-
creased plasma levels of triglycerides and FFA, as well
as increased fat pad mass and insulin resistance, we
expected that some of the metabolic consequences of
overexpressing apoA-II were likely to be manifested as
altered adipocyte metabolism. We examined adipose tis-
sue metabolism by comparing the rates of triglyceride
hydrolysis from epididymal and retroperitoneal fat pads
removed from fasted apoA-II transgenic and control mice.
As shown in Fig. 5, glycerol released from the hydrolysis of
triglycerides was signiﬁcantly reduced in both the epidid-
ymal and retroperitoneal fat pads from apoA-II transgenic
mice compared with control mice. These experiments
were repeated four times with totally consistent results.
Because the fasting insulin levels and glucose clearance
studies suggested insulin resistance in the apoA-II trans-
genic mice, we examined uptake of 2-deoxy-[U-
14C]glu-
cose in isolated soleus muscles of animals that had been
fasted overnight. In experiments in which 2-deoxy-[U-
14C]glucose uptake was determined immediately after re-
moval of the tissue from the animal without the addition of
exogenous insulin, rates of uptake were similar between
muscles obtained from apoA-II transgenic and control
mice (Fig. 6). However, when uptake was again deter-
mined in experiments where exogenous insulin (2 mU/
ml) was added to the incubation media, the rate of
2-deoxy-[U-
14C]glucose uptake was signiﬁcantly increased
in control animals compared with the apoA-II transgenic
mice (Fig. 6).
FIG. 3. Glucose clearance is delayed in apoA-II transgenic mice. After
an overnight fast, plasma clearance of a bolus of glucose was deter-
mined in apoA-II transgenic and control mice. To reduce the stress
effects of repeated bleeding, each animal was bled only once. Each data
point represents the mean 6 SE of nine different animals that were
bled only at that time point. A: Glucose levels expressed in milligram per
deciliter. B: Insulin levels expressed in picograms per milliliter. The
Student’s t test was used to test for differences between control and
apoA-II transgenic mice. *Signiﬁcantly different from control (P <
0.05).
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The apoA-II transgenic mice are insulin resistant, as dem-
onstrated by higher fasting plasma levels of insulin and a
delayed clearance of glucose bolus (Figs. 2 and 3). The
delay in glucose clearance appears to be primarily a
consequence of insulin resistance and not impaired insulin
secretion because the plasma insulin–to–glucose ratios
during the glucose clearance studies were signiﬁcantly
increased in the apoA-II transgenic mice compared with
controls. Adipose tissue in the apoA-II transgenic mice,
however, may not be resistant to insulin action. In incu-
bations of adipose tissue explants obtained from animals
that had been fasted overnight, rates of triglyceride
hydrolysis were reduced by ;50% in tissue from apoA-II
transgenic mice compared with controls (Fig. 5). This
diminished triglyceride hydrolysis most likely reﬂects a
normal response of the adipose tissue to the elevated
fasting insulin levels. Furthermore, it is likely that the
response of adipose tissue to the elevated plasma insulin
levels contributes to the increased fat deposition in the
apoA-II transgenic mice. The increased adiposity in the
apoA-II transgenic mice is evident in mice of all ages. In
animals as young as 6–8 weeks, there is a signiﬁcant
difference in fat pad mass between apoA-II transgenic and
control mice, even though there is no signiﬁcant difference
in body weight (data not shown). As the animals mature,
the difference in adiposity between the apoA-II transgenic
and control mice increases, until 6 months of age when the
difference is so great that the total body weight between
the two strains becomes signiﬁcantly different (Fig. 4).
Several studies have demonstrated a positive correlation
between adipose mass and plasma leptin levels. The ele-
vated plasma leptin levels in the apoA-II transgenic mice
are most likely a consequence of the increased adipose
mass rather than altered rates of secretion by the adipose
tissue. This evidence is supported by the observation that
the ratio of leptin to percent total body fat is similar
between the control and apoA-II transgenic mice (0.18 6
0.03 and 0.20 6 0.04 for control and apoA-II transgenic
mice, respectively).
When we initially observed that the apoA-II transgenic
mice were insulin resistant, we hypothesized that the in-
crease in plasma FFA levels was a consequence of in-
creased rates of triglyceride hydrolysis from adipose tissue,
a hypothesis disproved by the fat pad incubation studies
(Fig. 5). Plasma triglycerides are hydrolyzed in peripheral
vascular beds, primarily in adipose tissue and skeletal mus-
cle, and the majority of the fatty acids released into the
plasma are taken up locally by these tissues. However,
;15% of the FFAs released from hydrolysis of triglycerides
in the peripheral capillary beds escape local uptake and
return to the liver. Because plasma triglycerides are ele-
vated ;10-fold in the apoA-II transgenic mice, the increase
in plasma FFAs may be due, primarily, to the greater mass
of FFAs “escaping” local uptake.
FIG. 4. Fat mass is increased in the apoA-II transgenic mice. Epididymal
(epi) and retroperitoneal (retro) fat pad masses, as well as whole body
fat content, were determined in apoA-II transgenic and control mice
that had been maintained on standard Purina lab chow. Plasma leptin
levels were also determined by ELISA. A: Body weight in grams. B:
Retroperitoneal fat pad weight per body weight. C: Epididymal fat pad
weight per body weight. D: Whole body fat mass expressed as percent
of dry body weight. E: Plasma leptin levels in picograms per milliliter.
All values are given as the mean 6 SE. n 5 15 for both control and
apoA-II transgenic groups. The Student’s t test was used to test for
differences between control and apoA-II transgenic mice. *Signiﬁcant-
ly different from control (P < 0.05).
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in the apoA-II transgenic mice, ketone body production
does not appear to be increased (Table 1). As a conse-
quence of decreased glucose utilization by peripheral
tissues, as well as increased plasma insulin levels, hepatic
lipogenesis and triglyceride production may be increased
in the apoA-II transgenic mice, with a corresponding
decrease in rates of fatty acid oxidation. The normal
plasma ketone body concentration in the apoA-II trans-
genic mice is consistent with the observation that in
human insulin resistance and type 2 diabetes, plasma
ketone body concentrations are usually not elevated (27).
The increased ratio of apoB48 to apoB100 in the apoA-II
transgenic mice is consistent with a normal response of
hepatic apoB production to the elevated insulin levels
(Fig. 1). Unlike humans, mouse liver can synthesize both
apoB48 and apoB100. The editing of the apoB message has
been shown to be regulated by insulin, which increases the
proportion of apoB48 secreted (28).
The apoA-II transgenic mice are clearly insulin resistant;
however, as described above, adipose tissue and liver
appear to respond normally to the elevated plasma insulin
levels. Our data are consistent with skeletal muscle being
the insulin-resistant tissue in the apoA-II transgenic mice.
Whereas there are clearly cases of adipose tissue insulin
resistance, reduced utilization of glucose by skeletal mus-
cle largely accounts for systemic insulin resistance (29).
To investigate if skeletal muscle in the apoA-II trans-
genic mice is insulin resistant, we determined rates of
2-deoxy-[U-
14C]glucose uptake in the isolated soleus mus-
cle. In one set of experiments, the rate of uptake of
2-deoxy-[U-
14C]glucose was begun immediately upon re-
moval of the muscle from the animal. In these experi-
ments, there was no signiﬁcant difference in rates of
uptake (Fig. 6). We interpreted these results to indicate
insulin resistance in skeletal muscle from the apoA-II
FIG. 5. Adipose tissue from apoA-II transgenic mice exhibits signiﬁ-
cantly less triglyceride hydrolysis than adipose tissue from control
mice. Adipose tissue from epididymal (epi) and retroperitoneal (retro)
fat pads was obtained from apoA-II transgenic (apoA-II) and control
(control) mice that had been fasted overnight. Aliquots of the adipose
tissue were incubated for1ha t37°C, and the glycerol released from
hydrolysis of triglycerides was determined. Data are the mean 6 SE of
triglycerides hydrolyzed expressed in milligrams per hour per gram of
tissue. n 5 10 for both control and apoA-II transgenic groups. The
Student’s t test was used to test for differences between control and
apoA-II transgenic mice. *Signiﬁcantly different from control (P <
0.05).
FIG. 6. Skeletal muscle from apoA-II transgenic mice exhibits signiﬁ-
cantly less uptake of 2-deoxy-[U-
14C]glucose. The soleus muscles were
isolated from apoA-II transgenic and control mice that had been fasted
overnight, as described in RESEARCH DESIGN AND METHODS. Uptake of
2-deoxy-[U-
14C]glucose (2.5 mCi/ml) was determined by incubating the
muscles for 20 min in Krebs-Henseleit buffer that contained 5.5 mmol/l
glucose and 1% BSA, with or without exogenous insulin added. A: Upon
removal, the muscles were immediately incubated as described above
without the addition of exogenous insulin. B: Upon removal, the
muscles underwent a 20-min preincubation in Krebs-Henseleit buffer
(without 2-deoxy-[U-
14C]glucose) that contained porcine insulin (2
mU/ml). At the end of the preincubation period, the tissue was trans-
ferred to new vials and incubated in Krebs-Henseleit buffer that
contained insulin (2 mU/ml) as well as 2-deoxy-[U-
14C]glucose (2.5
mCi/ml). Data are the mean 6 SE of radioactivity incorporated, ex-
pressed as dpm per gram of tissue per 20 min. n 5 7 for both control
and apoA-II transgenic groups in each set of experiments. The Stu-
dent’s t test was used to test for differences between control and
apoA-II transgenic mice. *Signiﬁcantly different from control (P <
0.05).
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exposed in vivo to insulin levels that were approximately
twofold higher in the apoA-II transgenic mice, but uptake
was not signiﬁcantly increased. The higher fasting insulin
levels had, in effect, normalized uptake of glucose by the
skeletal muscle in the apoA-II transgenic mice. We then
repeated the uptake studies in a second set of experiments
in which exogenous insulin was added to the incubation
media at a concentration of 2 mU/ml, as described in
RESEARCH DESIGN AND METHODS. This concentration of insulin
was reported to promote maximal stimulation of glucose
uptake in rat soleus muscle (24). After incubation in the
presence of the high insulin concentration, rates of 2-de-
oxy-[U-
14C]glucose uptake by soleus muscle from control
mice were signiﬁcantly increased compared with muscles
from the apoA-II transgenic mice, consistent with insulin
resistance in the apoA-II transgenic mice (Fig. 6).
The link between increased adipose mass and insulin
resistance has been recognized for many years, but the
etiology of obesity-related insulin resistance is unclear.
Increased plasma FFA concentrations have been hypoth-
esized to contribute to insulin resistance by increasing
utilization of fatty acid by muscle as a consequence of
the concentration-dependent uptake of FFA (30–32). In-
creased fatty acid oxidation is then believed to inhibit
glucose oxidation and glycolysis, with subsequent inhibi-
tion of glucose uptake. On the other hand, some evidence
suggests that the basis of skeletal muscle insulin resis-
tance in obesity may actually be an impaired capacity for
use of plasma FFA (33–35). Use of FFA for energy by
skeletal muscle is reported to be reduced in obesity. There
is evidence that impaired oxidation of fat may be a con-
tributing factor to weight gain (36,37). The activity of car-
nitine palmitoyl transferase (CPT) in muscle has also been
negatively correlated with visceral fat mass, and rates of
FFA uptake have been correlated with CPT activity (38).
These studies suggest that decreased oxidative capacity
and use of FFA by skeletal muscle can result in skeletal
muscle insulin resistance and increased adiposity, consis-
tent with the phenotype in the apoA-II transgenic mice.
Data from both animal and human studies have demon-
strated that the accumulation of triglyceride within skele-
tal muscle is associated with skeletal muscle insulin
resistance (39,40). The triglyceride content of skeletal
muscle was signiﬁcantly increased in the apoA-II trans-
genic mice (Table 1). Thus, these studies suggest that
decreased use of FFA by skeletal muscle could initiate a
metabolic chain of events leading to the observed hyper-
triglyceridemic phenotype in apoA-II transgenic mice.
But how can an alteration in an apolipoprotein on HDL
affect FFA use by skeletal muscle? One potential mecha-
nism could involve CD36, a member of the scavenger
receptor class B family of receptors (41), which is known
to bind HDL and to be expressed on adipocytes, skeletal
muscle, and other cells types that are involved in the rapid
turnover of fatty acids (42). The identiﬁcation of CD36 as
a gene involved in FFA metabolism and glucose utilization
supports this conclusion. Evidence suggests that CD36
may be involved in mediating an intracellular signaling
pathway in response to ligand binding (43). Such a path-
way could support an additional mechanism for CD36-
mediated regulation of FFA and triglyceride metabolism in
addition to a role in FFA uptake. Mice with a null mutation
for CD36 had increased plasma HDL cholesterol, triglyc-
erides, and FFA similar to the phenotype in the apoA-II
transgenic mice (44). Furthermore, muscle-speciﬁc over-
expression of CD36 in mice increased muscle fatty acid
oxidation, reduced plasma triglycerides and FFA, and in-
creased plasma glucose and insulin (45). Interestingly,
these mice also had signiﬁcantly reduced adipose mass.
These data demonstrate that CD36 has effects on virtually
everyaspectofthephenotypeobservedintheapoA-IItrans-
genic mice. We hypothesize that overexpression of apoA-II
alters HDL composition such that HDL interaction with
skeletal muscle CD36 is impaired, resulting in reduced use
of FFAs for energy by skeletal muscle and the subsequent
effects on skeletal muscle insulin resistance and increased
fat mass as discussed above. Consistent with this hypoth-
esis is the additional observation that ultracentrifugally
isolated HDL from apoA-II transgenic mice exhibit mark-
edly reduced binding to the CD36 receptor in cell culture
(F.C. deBeer, personal communication).
Whereas the apoA-II transgenic mice are not diabetic,
they are insulin resistant and mimic the human impaired
glucose tolerance (IGT) phenotype. Individuals with IGT
have an increased susceptibility to atherosclerotic disease
associated with known risk factors including hyperten-
sion, hyperlipidemia, and adiposity (46–48). Moreover, in-
dividuals with IGT are at higher risk than the general
population for the development of type 2 diabetes. Thus,
overexpression of apoA-II, by causing insulin resistance and
impaired tolerance to a glucose load, may predispose an
individual to the development of frank type 2 diabetes,
which may manifest itself under the appropriate dietary
challenges, with aging, or on appropriate genetic back-
grounds.
Insulin secretion does not appear to be signiﬁcantly
impaired in the apoA-II transgenic mice under the present
conditions. Because impaired insulin secretion is a key
component in the development of type 2 diabetes, this is
the most likely reason why the apoA-II transgenic mice did
not become diabetic. Aging is associated with a dimin-
ished insulin secretory response (49). Also, age has been
demonstrated to be an important factor in the develop-
ment of diabetes in another mouse model (50). The mice in
the present study were tested at a relatively young age (6
months). Thus, the phenotype in older apoA-II transgenic
mice could be altered in such a manner that diabetes
would develop. In addition, the insulin resistance in the
apoA-II transgenic mice appears to be localized to muscle
and not adipose tissue under the present conditions.
Tissue-speciﬁc muscle insulin resistance does not appear
to cause diabetes in mice (51). Therefore, the apoA-II
transgenic mice may also require additional genetic fac-
tors to develop type 2 diabetes.
Several lines of evidence suggest that the effects of
apoA-II overexpression observed in the present study are
not a nonphysiological response to high levels of apoA-II
but, indeed, also occur with lower plasma apoA-II levels.
The effects of apoA-II on plasma FFA levels were observed
in genetic studies with common inbred strains of mice as
well as with human families enriched for heart disease
(10). Also, mice lacking apoA-II had decreased plasma
FFA levels and increased insulin sensitivity (18).
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traits referred to as “syndrome X” or “insulin resistance
syndrome,” which includes increased adiposity, elevated
insulin levels, elevated plasma triglyceride and FFA levels,
reduced HDL levels, and hypertension (11,12). These traits
are remarkably similar to those aspects of the phenotype
that we have thus far examined in the apoA-II transgenic
mice, with the exception of the HDL levels. Plasma HDL
cholesterol is increased rather than decreased in the
apoA-II transgenic mice. Many studies have demonstrated
the usefulness of the mouse as an experimental model to
investigate aspects of lipoprotein metabolism relevant to
human physiology. However, as with any animal model,
some differences will be observed when applying the re-
sults to other species. Although species differences may
contribute to the fact that the apoA-II transgenic model of
the insulin resistance syndrome does not have low HDL,
we believe that another factor is as likely to explain this
difference. Numerous studies in humans and various ani-
mal models, including the mouse, have demonstrated that
HDLs are a heterogeneous group of particles that differ in
structure and function. Although total HDL cholesterol is
elevated in the transgenic mice overexpressing mouse
apoA-II, there are also differences in the size and compo-
sition of the HDLs that make up the different subclasses
(6). This is supported by the observation that HDLs from
the apoA-II transgenic mice are not as protective as HDLs
from control mice in preventing the oxidation of LDL in a
cell culture model of the artery wall (2). Evidently, the
subfraction of HDLs important for this protective effect is
reduced in the apoA-II transgenic mice even though total
HDL is increased. Although total HDL cholesterol is ele-
vated in the apoA-II transgenic mice, we cannot rule out
the possibility that certain HDL subfractions, which may
be metabolically important to the insulin resistance syn-
drome, are actually decreased.
Alterations in plasma lipoprotein metabolism have usu-
ally been assumed to be secondary to insulin resistance
and adiposity (52,53). Our observations now indicate that
a primary disturbance in lipoprotein metabolism can result
in several traits associated with insulin resistance, consis-
tent with the hypothesis (54) that insulin resistance and
type 2 diabetes can, under certain circumstances, be
related primarily to altered lipid metabolism rather than
glucose metabolism. Our data suggest that variations in
the expression and structure of apoA-II may contribute to
insulin resistance and related traits in humans. The possi-
bility is supported by the ﬁnding that the apoA-II gene
segregates with plasma FFA levels in human pedigrees
enriched for coronary artery disease (10). Furthermore,
two recent family studies, involving the Pima Indian (55)
and Utah Caucasian (56) pedigrees, observed linkage of
type 2 diabetes with the apoA-II locus on human chromo-
some 1. Our results indicate that apoA-II is an excellent
candidate gene for these linkage ﬁndings.
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